Physician profile
Kenneth Alonso
NPI 1962580829
$7,280.07
in general payments reported to CMS, 2019-2025
29 companies · $968 in 2025
The $968 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $917 · 2021: $1,096 · 2022: $1,017 · 2023: $1,225 · 2024: $1,307 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,898.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,399.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $617.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.14 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $252.55 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $239.04 | 2019-2025 | |
| Abbvie INC. | $227.31 | 2019-2024 | Ubrelvy |
| Amgen INC. | $195.78 | 2019-2025 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $186.05 | 2019-2023 | |
| Exact Sciences Corporation | $170.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $166.80 | 2023-2025 | Veozah |
| Amneal Pharmaceuticals LLC | $158.25 | 2020-2025 | Unithroid |
| Medtronic, INC. | $158.07 | 2024 | In.Pact Admiral |
| Bayer Healthcare Pharmaceuticals INC. | $155.29 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.94 | 2019-2023 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $121.85 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $119.96 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $116.33 | 2019-2022 | |
| Shield Therapeutics INC | $104.39 | 2022-2025 | Accrufer |
| Amarin Pharma, INC. | $78.58 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $39.92 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.80 | 2021-2024 | Spravato |
| Hologic Sales and Service, LLC | $36.54 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $31.78 | 2021 | |
| Corcept Therapeutics | $15.30 | 2025 | Korlym |
| Medtronic Vascular, INC. | $15.18 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2022 | |
| Genentech USA, INC. | $12.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.